Cost-Benefit Analysis of Novel Antiviral Ritonavir in the Active Duty U.S. Military Population

Mil Med. 2022 Aug 25;187(9-10):274-275. doi: 10.1093/milmed/usab552.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antiviral Agents / therapeutic use
  • Cost-Benefit Analysis
  • Humans
  • Military Personnel*
  • Ritonavir / pharmacology
  • Ritonavir / therapeutic use
  • United States

Substances

  • Antiviral Agents
  • Ritonavir